OpenURL Connection Search

Select item for more details and to access through your institution.

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer.
Published in:
2014
By:
- von Pawel, Joachim;
- Harvey, Jimmie H;
- Spigel, David R;
- Dediu, Mircea;
- Reck, Martin;
- Cebotaru, Cristina L;
- Humphreys, Robin C;
- Gribbin, Matthew J;
- Fox, Norma Lynn;
- Camidge, D Ross
Publication type:
Journal Article
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non--Small-Cell Lung Cancer.
Published in:
Clinical Lung Cancer, 2014, v. 15, n. 3, p. 188, doi. 10.1016/j.cllc.2013.12.005
By:
- von Pawel, Joachim;
- Harvey, Jimmie H.;
- Spigel, David R.;
- Dediu, Mircea;
- Reck, Martin;
- Cebotaru, Cristina L.;
- Humphreys, Robin C.;
- Gribbin, Matthew J.;
- Fox, Norma Lynn;
- Camidge, D. Ross
Publication type:
Article
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Published in:
Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0417-z
By:
- Verstovsek, Srdan;
- Mesa, Ruben A.;
- Gotlib, Jason;
- Gupta, Vikas;
- DiPersio, John F.;
- Catalano, John V.;
- Deininger, Michael W. N.;
- Miller, Carole B.;
- Silver, Richard T.;
- Talpaz, Moshe;
- Winton, Elliott F.;
- Harvey Jr., Jimmie H.;
- Arcasoy, Murat O.;
- Hexner, Elizabeth O.;
- Lyons, Roger M.;
- Paquette, Ronald;
- Raza, Azra;
- Jones, Mark;
- Kornacki, Deanna;
- Kang Sun
Publication type:
Article
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Published in:
British Journal of Haematology, 2013, v. 161, n. 4, p. 508, doi. 10.1111/bjh.12274
By:
- Verstovsek, Srdan;
- Mesa, Ruben A.;
- Gotlib, Jason;
- Levy, Richard S.;
- Gupta, Vikas;
- DiPersio, John F.;
- Catalano, John V.;
- Deininger, Michael;
- Miller, Carole;
- Silver, Richard T.;
- Talpaz, Moshe;
- Winton, Elliott F.;
- Harvey, Jimmie H.;
- Arcasoy, Murat O.;
- Hexner, Elizabeth;
- Lyons, Roger M.;
- Paquette, Ronald;
- Raza, Azra;
- Vaddi, Kris;
- Erickson‐Viitanen, Susan
Publication type:
Article

Found: 4

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer.

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non--Small-Cell Lung Cancer.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.